Systemic delivery of atropine sulfate by the microdose dry-powder inhaler

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 1, 2013, Pages 46-55

  Corcoran, T E ^a   Venkataramanan, R ^b   Hoffman, R M ^a   George, M P ^a   Petrov, A ^a   Richards, T ^a   Zhang, S ^b   Choi, J ^c   Gao, Y Y ^b   Oakum, C D ^d   Cook, R O ^d   Donahoe, M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Monmouth Junction NJ 08852 USA   (United States)

Author keywords

anticholinergic; atropine allergy; chemical weapon; nerve gas antidote; systemic aerosol delivery

Indexed keywords

ATROPINE; DIPHENHYDRAMINE;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG HYPERSENSITIVITY; DRUG MICRODOSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; SELF INJECTION;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANTIDOTES; AREA UNDER CURVE; ATROPINE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EXCIPIENTS; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; YOUNG ADULT;

EID: 84873388432     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0948     Document Type: Article

References (20)

1. Schrickel JW, Lewalter T, Luderitz B, Nickenig G, Klehr HU, and Rabe C: Recovery from ultra-high dose organophosphate poisoning after "In-the-field" antidote treatment: potential lessons for civil defense. J Emerg Med. 2009;37:279-282
2. Pawar KS, Bhoite RR, Pillay CP, Chavan SC, Malshikare DS, and Garad SG: Continuous pralidoxime infusion versus repeated bolus injection to treat organophosphorus pesticide poisoning: a randomised controlled trial. Lancet. 2006;368 (9553):2136-2141 (Pubitemid 44894558)
3. Orma PS, and Middleton RK: Aerosolized atropine as an antidote to nerve gas. Ann Pharmacother. 1992;26:937-938
4. Zavala DC, Godsey K, and Bedell GN: The response to atropine sulfate given by aerosol and intramuscular routes to patients undergoing fiberoptic bronchoscopy. Chest. 1981; 79:512-515 (Pubitemid 11101805)
5. Harrison LI, Smallridge RC, Lasseter KC, Goldlust MB, Shamblen EC, Gam VW, Chang SF, and Kvam DC: Comparative absorption of inhaled and intramuscularly administered atropine. Am Rev Respir Dis. 1986;134:254-257 (Pubitemid 16046904)
6. Kehe CR, Lasseter KC, Miller NC, Wick KA, Shamblen EC, Ekholm BP, Sandahl JH, Chang SF, Goldlust MB, and Kvam DC: Comparative absorption of atropine from a metereddose inhaler and an intramuscular injection. Ther Drug Monit. 1992;14:132-134
7. 3M Riker: NDA 20-056, application to market a new drug for human use, atropine sulfate metered-dose aerosol. 1990
8. United States Food and Drug Administration. Use of ozonedepleting substances; removal of essential use designations (direct final rule). Fed Regist. 2006;71:235
9. Heyder J, Gebhardt J, Rudolf G, Schiller CF, and Stahlhofen W: Deposition of particles in the human respiratory tract in the size range of 0.005-15 micron. J Aerosol Sci. 1986;17:811-825 (Pubitemid 17492310)
10. Heyder J: Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1:315-320
11. Brunton L, Goodman L, Blumenthal D, and Buxton I: Goodman and Gilman's Manual of Pharmacology and Therapeutics. McGraw-Hill Professional, New York, NY; 2007
12. United States Pharmacopeial Convention. The United States Pharmacopeia, Chapter 601: Aerosols, Metered-Dose Inhalers, and Dry Powder Inhalers. 2004
13. AtroPen- drug label. Meridian Medical Technologies, Inc., subsidiary of King Pharmaceuticals, Bristol, TN
14. Decraene T, and Goossens A: Contact allergy to atropine and other mydriatic agents in eye drops. Contact dermatitis. 2001;45:309-310 (Pubitemid 33032981)
15. Hague JD, and Derr JJ: Military implications of atropine hypersensitivity. Mil Med. 2004;169:389-391 (Pubitemid 38987209)
16. Shipley D, and Ormerod AD: Drug-induced urticaria. Recognition and treatment. Am J Clin Dermatol. 2001;2:151-158
17. Ali R, Jain GK, Iqbal Z, Talegaonkar S, Pandit P, Sule S, Malhotra G, Khar RK, Bhatnagar A, and Ahmad FJ: Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine 2009;5:55-63
18. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, Petrucci RE, Boss AH, and Richardson PC: Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244-2253
19. Dinh K, Myers DJ, Glazer M, Shmidt T, Devereaux C, Simis K, Noymer PD, He M, Choosakul C, Chen Q, and Cassella JV: In vitro aerosol characterization of Staccato- Loxapine. Int J Pharm. 2011;403:101-108
20. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, and Dodick DW: MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51:507-517.